The objective of this project is to develop novel diagnostic biomarkers of Sjögren’s disease to better characterize patient phenotypic subgroups associated with clinical features and symptoms. If successful, these biomarkers will help establish clinical diagnostic criteria which are sensitive to pre-symptomatic biologically-evident disease (i.e., early disease). Furthermore, molecular characterization of patient subpopulations, and firm understanding of their relation to clinical features, will allow alignment of critical pathways and cell types with therapeutic assets, both existing and in development. Molecular classifications will also provide improved methods for patient (severity) stratification. Overall, these data will be a useful source for understanding previous and ongoing clinical trial responses, and in the rationale design of future trials.

Learn more about this project by viewing the project one-pager.

  • Perform multi-dimensional molecular characterization of the disease spectrum in salivary gland tissues of a diverse cohort of Sjögren’s disease, sicca, and healthy populations to test for associations with clinical sub-phenotypes​.

  • Identify blood-based antibody and protein signatures that correlate with salivary gland signatures and clinical sub-phenotypes for development of minimally invasive biomarkers.

  • Align and compare SjD subsets based on minor salivary gland transcriptomics with previously proposed SjD subsets defined by peripheral blood gene expression.



Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients